Victory Capital Management Inc. Has $8.43 Million Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Victory Capital Management Inc. increased its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) by 198.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 76,833 shares of the medical equipment provider’s stock after buying an additional 51,128 shares during the period. Victory Capital Management Inc.’s holdings in Lantheus were worth $8,432,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the business. GAMMA Investing LLC grew its position in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 208 shares during the period. Signaturefd LLC boosted its stake in Lantheus by 40.5% during the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock worth $35,000 after acquiring an additional 92 shares during the last quarter. Nkcfo LLC acquired a new position in Lantheus during the second quarter valued at approximately $47,000. UMB Bank n.a. increased its stake in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock valued at $47,000 after purchasing an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus in the 3rd quarter valued at $51,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

LNTH has been the topic of several research analyst reports. Truist Financial reaffirmed a “buy” rating and set a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a research note on Friday, November 8th. B. Riley boosted their price objective on Lantheus from $105.00 to $146.00 and gave the company a “buy” rating in a research report on Thursday, July 25th. Redburn Atlantic assumed coverage on shares of Lantheus in a report on Tuesday, September 3rd. They set a “buy” rating and a $175.00 target price on the stock. JMP Securities lowered their price objective on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating for the company in a research report on Thursday, November 7th. Finally, StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday. Two research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $122.50.

Lantheus Price Performance

Shares of NASDAQ LNTH opened at $87.32 on Friday. The business has a 50-day moving average of $103.76 and a 200-day moving average of $96.59. The stock has a market capitalization of $6.07 billion, a price-to-earnings ratio of 14.53 and a beta of 0.51. Lantheus Holdings, Inc. has a fifty-two week low of $50.20 and a fifty-two week high of $126.89.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.